Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
HOLLISTON, Mass., April 23, 2018 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its first quarter 2018 after market trading hours on Wednesday, May 2, 2018. A conference call to discuss the company's first quarter 2018 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-888-771-4371, or international: 1-847-585-4405, and referencing the conference ID# 46853827.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through May 9, 2018.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACT:
Corey Manchester
Director, Finance and Investor Relations
Tel: 508 893 8999
